Format

Send to

Choose Destination
BMC Cancer. 2016 May 14;16:312. doi: 10.1186/s12885-016-2339-5.

Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer.

Author information

1
Medical Oncology 2 Unit, Istituto Oncologico Veneto I.R.C.C.S, Via Gattamelata 64, 35128, Padova, Italy. laura.bonanno@ioveneto.it.
2
Laboratory of translational Oncology, Pangaea Biotech, Sabino de Arana, 5-9, Barcelona, Spain.
3
Medical Oncology Service, Hospital de Sant Pau, Sant Antoni Maria Claret, 167, Barcelona, Spain.
4
Autonomous University of Madrid, Ciudad Universitaria de Cantoblanco, 28049, Madrid, Spain.
5
Department Obstetrics, Gynecology and Reproduction, Dexeus Universisty Hospital, av Sabino de Arana 5-9, Barcelona, Spain.
6
Hospital du Cluzeau, 23, rue Larey, Limoges, France.
7
Medical Oncology, General Hospital of Alicante, 11, Baeza, 03010, Alicante, Spain.
8
Medical Oncology 2 Unit, Istituto Oncologico Veneto I.R.C.C.S, Via Gattamelata 64, 35128, Padova, Italy.
9
Cytology and Pathology, Università degli Studi di Padova, Via Gabelli 61, Padova, Italy.
10
Catalan Institute of Oncology, Barcelona, Spain.
11
Catalan Institute of Oncology, Barcelona, Spain. rrosell@iconcologia.net.

Abstract

BACKGROUND:

BRCA1 is a main component of homologous recombination and induces resistance to platinum in preclinical models. It has been studied as a potential predictive marker in lung cancer. Several proteins modulate the function of BRCA1. The E3 ubiquitin ligase HERC2 facilitates the assembly of the RNF8-UBC13 complex to recruit BRCA1 to DNA damage sites. The combined analysis of multiple components of the pathway leading to the recruitment of BRCA1 at DNA damage sites has the potentiality to improve the BRCA1 predictive model.

METHODS:

We retrospectively analyzed 71 paraffin-embedded tumor samples from advanced non-small-cell lung cancer patients treated with first-line platinum based chemotherapy and measured the mRNA expression levels of BRCA1, RNF8, UBC13 and HERC2 using real-time PCR. The mRNA expression was categorized using median value as cut-off point.

RESULTS:

The median progression-free survival of all 71 patients was 7.2 months whereas the median overall survival of the study population was 10.7 months. Among patients with low BRCA1 expression, the median PFS was 7.4 months in the presence of low HERC2 levels and 5.9 months for patients expressing high HERC2 levels (p = 0.01). The median OS was 15.3 months for patients expressing low levels of both genes and 7.4 months for those with low BRCA1 but high HERC2 (p = 0.008). The multivariate analysis showed that among patients with Eastern Cooperative Oncology Group performance status 0-1, the combined low expression of both BRCA1 and HERC2 clearly reduced the risk of progression (p = 0.03) and of death (p = 0.004).

CONCLUSIONS:

These findings confirm the potentiality of integrated DNA repair components analysis in predicting the sensitivity to platinum in lung cancer. The study indicates a predictive role for HERC2 mRNA expression and paves the way for further refinement of the BRCA1 predictive model.

KEYWORDS:

BRCA1; DNA repair; HERC2; Non-small-cell lung cancer; Platinum; Predictive markers

PMID:
27179511
PMCID:
PMC4868003
DOI:
10.1186/s12885-016-2339-5
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center